453 related articles for article (PubMed ID: 32345666)
1. Tumor microRNAs Identified by Small RNA Sequencing as Potential Response Predictors in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy.
Machackova T; Trachtova K; Prochazka V; Grolich T; Farkasova M; Fiala L; Sefr R; Kiss I; Skrovina M; Dosoudil M; Berindan-Neagoe I; Svoboda M; Slaby O; Kala Z
Cancer Genomics Proteomics; 2020; 17(3):249-257. PubMed ID: 32345666
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.
Svoboda M; Sana J; Fabian P; Kocakova I; Gombosova J; Nekvindova J; Radova L; Vyzula R; Slaby O
Radiat Oncol; 2012 Nov; 7():195. PubMed ID: 23167930
[TBL] [Abstract][Full Text] [Related]
3. Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer.
Yu J; Li N; Wang X; Ren H; Wang W; Wang S; Song Y; Liu Y; Li Y; Zhou X; Luo A; Liu Z; Jin J
Oncotarget; 2016 Sep; 7(39):64233-64243. PubMed ID: 27572313
[TBL] [Abstract][Full Text] [Related]
4. Serum miR-125b is a non-invasive predictive biomarker of the pre-operative chemoradiotherapy responsiveness in patients with rectal adenocarcinoma.
D'Angelo E; Fassan M; Maretto I; Pucciarelli S; Zanon C; Digito M; Rugge M; Nitti D; Agostini M
Oncotarget; 2016 May; 7(19):28647-57. PubMed ID: 27081702
[TBL] [Abstract][Full Text] [Related]
5. miR-194 as predictive biomarker of responsiveness to neoadjuvant chemoradiotherapy in patients with locally advanced rectal adenocarcinoma.
D'Angelo E; Zanon C; Sensi F; Digito M; Rugge M; Fassan M; Scarpa M; Pucciarelli S; Nitti D; Agostini M
J Clin Pathol; 2018 Apr; 71(4):344-350. PubMed ID: 28870889
[TBL] [Abstract][Full Text] [Related]
6. YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional study.
Senetta R; Duregon E; Sonetto C; Spadi R; Mistrangelo M; Racca P; Chiusa L; Munoz FH; Ricardi U; Arezzo A; Cassenti A; Castellano I; Papotti M; Morino M; Risio M; Cassoni P
PLoS One; 2015; 10(4):e0123759. PubMed ID: 25875173
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients.
Lopes-Ramos CM; Habr-Gama A; Quevedo Bde S; Felício NM; Bettoni F; Koyama FC; Asprino PF; Galante PA; Gama-Rodrigues J; Camargo AA; Perez RO; Parmigiani RB
BMC Med Genomics; 2014 Dec; 7():68. PubMed ID: 25496125
[TBL] [Abstract][Full Text] [Related]
8. miR-21, miR-99b and miR-375 combination as predictive response signature for preoperative chemoradiotherapy in rectal cancer.
Campayo M; Navarro A; Benítez JC; Santasusagna S; Ferrer C; Monzó M; Cirera L
PLoS One; 2018; 13(11):e0206542. PubMed ID: 30388154
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer.
Seo I; Lee HW; Byun SJ; Park JY; Min H; Lee SH; Lee JS; Kim S; Bae SU
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33692216
[TBL] [Abstract][Full Text] [Related]
10. Development of a long non-coding RNA signature for prediction of response to neoadjuvant chemoradiotherapy in locally advanced rectal adenocarcinoma.
Ferrando L; Cirmena G; Garuti A; Scabini S; Grillo F; Mastracci L; Isnaldi E; Marrone C; Gonella R; Murialdo R; Fiocca R; Romairone E; Ballestrero A; Zoppoli G
PLoS One; 2020; 15(2):e0226595. PubMed ID: 32023246
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-31 Emerges as a Predictive Biomarker of Pathological Response and Outcome in Locally Advanced Rectal Cancer.
Caramés C; Cristobal I; Moreno V; Marín JP; González-Alonso P; Torrejón B; Minguez P; Leon A; Martín JI; Hernández R; Pedregal M; Martín MJ; Cortés D; García-Olmo D; Fernández MJ; Rojo F; García-Foncillas J
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27271609
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07.
Helbling D; Bodoky G; Gautschi O; Sun H; Bosman F; Gloor B; Burkhard R; Winterhalder R; Madlung A; Rauch D; Saletti P; Widmer L; Borner M; Baertschi D; Yan P; Benhattar J; Leibundgut EO; Bougel S; Koeberle D
Ann Oncol; 2013 Mar; 24(3):718-25. PubMed ID: 23139259
[TBL] [Abstract][Full Text] [Related]
13. A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
Della Vittoria Scarpati G; Falcetta F; Carlomagno C; Ubezio P; Marchini S; De Stefano A; Singh VK; D'Incalci M; De Placido S; Pepe S
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1113-9. PubMed ID: 22172905
[TBL] [Abstract][Full Text] [Related]
14. High expression of microRNA-199a-5p is associated with superior clinical outcomes in patients with locally advanced rectal cancer.
Baek DW; Kim G; Kang BW; Kim HJ; Park SY; Park JS; Choi GS; Kang MK; Hur K; Kim JG
J Cancer Res Clin Oncol; 2020 Jan; 146(1):105-115. PubMed ID: 31781865
[TBL] [Abstract][Full Text] [Related]
15. Gene and MicroRNA Expression Are Predictive of Tumor Response in Rectal Adenocarcinoma Patients Treated With Preoperative Chemoradiotherapy.
Millino C; Maretto I; Pacchioni B; Digito M; De Paoli A; Canzonieri V; D'Angelo E; Agostini M; Rizzolio F; Giordano A; Barina A; Rajendran S; Esposito G; Lanfranchi G; Nitti D; Pucciarelli S
J Cell Physiol; 2017 Feb; 232(2):426-435. PubMed ID: 27225591
[TBL] [Abstract][Full Text] [Related]
16. microRNAs combined to radiomic features as a predictor of complete clinical response after neoadjuvant radio-chemotherapy for locally advanced rectal cancer: a preliminary study.
Losurdo P; Gandin I; Belgrano M; Fiorese I; Verardo R; Zanconati F; Cova MA; de Manzini N
Surg Endosc; 2023 May; 37(5):3676-3683. PubMed ID: 36639577
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor cells: A promising marker of predicting tumor response in rectal cancer patients receiving neoadjuvant chemo-radiation therapy.
Sun W; Li G; Wan J; Zhu J; Shen W; Zhang Z
Oncotarget; 2016 Oct; 7(43):69507-69517. PubMed ID: 27486758
[TBL] [Abstract][Full Text] [Related]
18. Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy.
Drebber U; Lay M; Wedemeyer I; Vallböhmer D; Bollschweiler E; Brabender J; Mönig SP; Hölscher AH; Dienes HP; Odenthal M
Int J Oncol; 2011 Aug; 39(2):409-15. PubMed ID: 21567082
[TBL] [Abstract][Full Text] [Related]
19. Standardized Index of Shape (SIS): a quantitative DCE-MRI parameter to discriminate responders by non-responders after neoadjuvant therapy in LARC.
Petrillo A; Fusco R; Petrillo M; Granata V; Sansone M; Avallone A; Delrio P; Pecori B; Tatangelo F; Ciliberto G
Eur Radiol; 2015 Jul; 25(7):1935-45. PubMed ID: 25577525
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiles of tumor regression grade in locally advanced rectal cancer after neoadjuvant chemoradiotherapy.
Saigusa S; Tanaka K; Toiyama Y; Matsushita K; Kawamura M; Okugawa Y; Hiro J; Inoue Y; Uchida K; Mohri Y; Kusunoki M
Oncol Rep; 2012 Sep; 28(3):855-61. PubMed ID: 22711167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
